CN103784684A - Xuemaian blood glucose lowering capsule with therapeutic action on diabetes - Google Patents
Xuemaian blood glucose lowering capsule with therapeutic action on diabetes Download PDFInfo
- Publication number
- CN103784684A CN103784684A CN201410064096.8A CN201410064096A CN103784684A CN 103784684 A CN103784684 A CN 103784684A CN 201410064096 A CN201410064096 A CN 201410064096A CN 103784684 A CN103784684 A CN 103784684A
- Authority
- CN
- China
- Prior art keywords
- diabetes
- blood
- xuemaian
- capsule
- blood glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a Xuemaian blood glucose lowering capsule with therapeutic action on diabetes, which is prepared from Panax notoginseng 10-40 parts and Daemonorops draco 10-60 parts by the steps of performing ultraviolet disinfection of Panax notoginseng and Daemonorops draco and sieving with a 50-90 mesh sieve separately, mixing according to the weight ratio in the technical scheme, stirring, and encapsulating. The invention uses Panax notoginseng and Daemonorops draco as components and reasonably compounds Panax notoginseng and Daemonorops draco, the obtained Xuemaian blood glucose lowering capsule with therapeutic action on diabetes is an ingenious combination of herbal pure herba bio-enzymes, has two-way regulation effect on blood coagulation and hematolysis, has great advantage in reconstructing human blood sugar stabilization system, can reduce blood sugar index, and has a distinct curative effect on macroangiopathy and diabetic foot of diabetics. The Xuemaian blood glucose lowering capsule has the advantages of low toxic and side effects after long-term administration, simple preparation method, easily-available raw materials, low cost, and good therapeutic effect.
Description
Technical field
The invention belongs to Chinese drug preparation, be specifically related to diabetictrunk angiopathy and the medicative one of diabetic foot tool to pacify Jiangtang capsule to the medicative blood vessels of diabetes tool.
Background technology
The sickness rate of China's diabetes is up to 5.7% at present, number of patients approximately 7,000 ten thousand people, at present also in the speed increase with example every days 3,000, show according to World Health Organization's statistics, the annual Diabetes Death number in the world is 3,800,000 people, with regard to a dead example, just have a diabetics every 30 seconds by amputation average every ten seconds.The current ill total number of persons of China has surmounted the U.S., and India becomes the first in the world, and China is every year for the medical fee of diabetics expenditure reaches more than 180 hundred million yuan.Diabetes as worldwide difficult medical problem due to very complicated method, the especially complication that not there is no so far radical cure of its pathogenesis, hard to guard against especially, fatality rate, the height of disability rate ranks front three.Show according to up-to-date diabetes study, the pathogenesis traditional Chinese medical science of diabetes is thought and is caused by human body deficiency of both QI and YIN from strategic height, should be caused by the deficiency of vital energy more precisely, only have the deficiency of vital energy just to match with " The Yellow Emperor's Canon of Internal Medicine " the five internal organs pathogenesis, according to " Huang di's Canon of Medicine ", " TCM basis theory ", " Chinese materia medica ", " Compendium of Materia Medica ", " diabetology " and other scientific theories are for instructing, in fact the traditional Chinese medical science has superiority in diabetes control, health therapy for diabetes and complication thereof can solve by dietetic therapy, by studying on pure book on Chinese herbal medicine, collection food, health product, medicine is integrated, improve the prevention of Chinese medicine, health care, therapeutic effect.
Studies show that according to diabetology, show to have 54 kinds of Chinese herbal medicine to there is hypoglycemic activity through zoopery, end the Chinese medicine that in December, 2007 state food drug surveilance office examines the treatment diabetes of promulgation and amount to 35 kinds, relate to pill, capsule, oral liquid, granule, tablet, 6 kinds of dosage forms of injection, wherein only a kind of is the effective ingredient extracting from Chinese medicine, but these drug ingredient compositions are various, virtually strengthened production cost.
Show according to up-to-date diabetology research, the Chinese medicinal plant composition with hypoglycemic activity mainly contains: terpenoid, insulin, peptide and amino acids, flavonoid, isoflavone aglycone, polysaccharide, thioether class, alkaloids, Coumarins and unsaturated fatty acids etc., they bring into play curative effect by different approach and target spot in the treatment of diabetes, its hypoglycemic effect is poor unlike Western medicine, and toxic and side effects is little.
Summary of the invention
According to above-mentioned elaboration, the object of the present invention is to provide the one that can play therapeutical effect to diabetics to the medicative blood vessels peace of diabetes tool Jiangtang capsule.
A kind of technical scheme to the medicative blood vessels peace of diabetes tool Jiangtang capsule provided by the invention is to be made up of the raw material of following weight portion:
10～40 parts of Radix Notoginseng, 10～60 parts of Sanguis Draxonis.
A kind of preparation method to the medicative blood vessels peace of diabetes tool Jiangtang capsule provided by the invention is:
By described Radix Notoginseng, Sanguis Draxonis carries out respectively disinfection by ultraviolet light, pulverizes respectively 50-90 mesh sieves, carries out mix and blend according to the components by weight of described technical scheme, is then distributed into capsule.
The present invention adopts the Radix Notoginseng, Sanguis Draxonis of integration of edible and medicinal herbs as component, reasonable compatibility, what obtain is pure herbal enzyme and the ingenious combination of beneficial microorganism to the medicative blood vessels peace of diabetes tool Jiangtang capsule, can reduce blood glucose, macroangiopathy and diabetic foot be had to remarkable therapeutical effect simultaneously.There is very large advantage to rebuilding blood sugar for human body stabilisation systems, long-term taking, toxic and side effects is little, and manufacture method is simple, and raw material is easy to get, and cost is low, good effect.
The specific embodiment
Below technical scheme of the present invention is clearly and completely described, obviously, described embodiment is only the present invention's part embodiment, rather than whole embodiment.Based on the embodiment in the present invention, those of ordinary skills, not making the every other embodiment obtaining under creative work prerequisite, belong to the scope of protection of the invention.
Compatibility of drugs of the present invention is reasonable, and its compatibility principle is:
Radix Notoginseng, just be acknowledged as since ancient times and there is significant blood circulation promoting and blood stasis dispelling, subduing swelling and relieving pain effect, there is " Radix Stephaniae Sinicae (Radix Stephaniae Dielsianae) ", the good reputation of " southern part of the country SHENCAO ", its effective active matter again higher than with more than Radix Ginseng, Radix Notoginseng is warm in nature, acrid in the mouth, be rich in saponin, flavonoid glycoside, Radix Salviae Miltiorrhizae acid potassium, there is scattered silt hemostasis, effect of subduing swelling and relieving pain, flavone compound in Radix Notoginseng has the blood supply of cardiac muscle of improvement, increase vessel wall elasticity, effect of coronary artery dilator, sitosterol and the blood fat reducing of daucosterol energy, Radix Notoginseng is to diabetes, cardiovascular patient is by the well effect for the treatment of, the present invention uses Radix Notoginseng to play dual regulation to blood coagulation and haemolysis, can blood sugar lowering.
Sanguis Draxonis, sweet in the mouth, sweet, property is put down, GUIXIN, liver, spleen channel, the present invention utilizes the compositions such as dracorhodin in Sanguis Draxonis, dracorubin, flavonol, chalcone, resinic acid, can blood sugar lowering to diabetics, the analgesic therapy of invigorating blood circulation, hemostasia and promoting granulation, inhibition thrombosis, promote plasmin activity.
This preparation is capsule, is to reduce dose, with the powder of the medical material replacement adjuvant that is used as medicine.
According to above-mentioned component and compatibility principle analysis, the open following examples of the present invention.
Embodiment 1:
Get: 10 parts of Radix Notoginseng, 15 parts of Sanguis Draxonis.
By described Radix Notoginseng, Sanguis Draxonis carries out respectively disinfection by ultraviolet light, pulverized respectively mix and blend after 80 mesh sieves, is then distributed into capsule.
Embodiment 2:
Get: 20 parts of Radix Notoginseng, 25 parts of Sanguis Draxonis.
By described Radix Notoginseng, Sanguis Draxonis carries out respectively disinfection by ultraviolet light, pulverized respectively mix and blend after 50 mesh sieves, is then distributed into capsule.
Embodiment 3:
Get: 10 parts of Radix Notoginseng, 30 parts of Sanguis Draxonis.
By described Radix Notoginseng, Sanguis Draxonis carries out respectively disinfection by ultraviolet light, pulverized respectively mix and blend after 90 mesh sieves, is then distributed into capsule.
Embodiment 4:
Get: 30 parts of Radix Notoginseng, 35 parts of Sanguis Draxonis.
By described Radix Notoginseng, Sanguis Draxonis carries out respectively disinfection by ultraviolet light, pulverized respectively mix and blend after 70 mesh sieves, is then distributed into capsule.
Embodiment 5:
Get: 30 parts of Radix Notoginseng, 30 parts of Sanguis Draxonis.
By described Radix Notoginseng, Sanguis Draxonis carries out respectively disinfection by ultraviolet light, pulverized respectively mix and blend after 60 mesh sieves, is then distributed into capsule.
To above-described embodiment 2 the medicative blood vessels of diabetes tool peace Jiangtang capsule is carried out to acute toxicity test, in the situation that not measuring animal acute toxicity (LD50), carried out maximum tolerance test.So that the medicative blood vessels of diabetes tool are pacified to Jiangtang capsule suspension 80g (crude drug)/kg, within 1st, give Kunming mouse gavage 2 times, Continuous Observation 14 days, records the performance of the toxicity of animal after medicine, and result animal is after medicine in 2h, movable minimizing, be rest state, its food ration, hair color, two just and active situation all without abnormal, find no other intoxicating phenomenon of drug-induced, none death of animal subject, approximately behave 50 times of clinical plan consumption of this dosage.
It is safe and reliable that the medicative blood vessels peace Jiangtang capsule of diabetes tool short-term in this dosage is taken, and also can infer thus that it is safer that the clinical plan consumption of people is taken in a short time.
To above-described embodiment 2 to the medicative blood vessels of diabetes tool peace Jiangtang capsule long term toxicity test, it is 4-8 week that the medicative blood vessels of diabetes tool peace Jiangtang capsule clinical taken to the course for the treatment of, according to the regulations of new drug research, the long term toxicity test that we have carried out the rat oral gavage administration of 24 weeks to it.After medicine 12 weeks, 24 weeks and drug withdrawal, after 2 weeks, were put to death respectively animal, do the inspection of the indices such as hematology, blood biochemical, histopathology, and result relatively has no overt toxicity with water matched group and reacts.Wherein high dose group: 40g (crude drug)/kg, is about 1/5 of the oral maximum tolerated dose of mice, 400 times of the clinical plan consumption of behaving; Middle dosage group: 20g (crude drug)/kg, is about 1/8 of the oral maximum tolerated dose of mice, 200 times of the clinical plan consumption of behaving; Low dose group: 10g (crude drug)/kg, is about 1/16 of the oral maximum tolerated dose of mice, 20 times of the clinical plan consumption of behaving.Result of the test shows, is safe, and also finds no retardance toxicity after drug withdrawal by above-mentioned dosage to (180 days) in the animals administer phase.This result has also pointed out the taking dose safety range of said preparation larger simultaneously, and safety clothes are longer with the phase.
Determining of grain weight, dose and the loading amount of embodiment 2.Grain is heavy: the total powder amount of embodiment 2 preparation prescription is 500g, makes 1000, every heavy 0.5g
Select " 0 " number capsule, handle frock examination, every between 0.41g～0.52g.
Oral dose: 6 of every days, every day three times.
For showing effect of the present invention, the present invention proves through clinical and experimental study: the clinical treatment experiment to the medicative blood vessels peace of diabetes tool Jiangtang capsule warp to 10 routine diabetes and complication sufferer thereof, show that the present invention has supplementing QI and nourishing YIN really, strengthening the body resistance, blood circulation promoting and blood stasis dispelling, the dredging collateral function that relieves the pain; Can effectively treat card and see thirsty polydipsia, pollakiuria is easily hungry, and body is thin weak, spontaneous sweating, dim complexion, numb limbs and tense tendons, diabetes and the complication thereof such as the dark ecchymosis of tongue; Can realize and reduce blood pressure and blood lipoid, blood vessel dilating, increases coronary flow, impels Thrombolysis, improves microcirculation, corrects hemorheological property, carries islet function, the therapeutic effect for the treatment of both the principal and secondary aspects of a disease, and total effective rate has reached 77.28%.Also show, the present invention is to internal organs such as the heart, liver, kidneys, all harmless, is a kind of safe without toxic side effect good medicine of effectively preventing and treating diabetes and complication thereof simultaneously.
Sufferer source: outpatient service 1 people, ward 9 people, add up to 10 people.The diabetes that patient selects card to see the every main symptom of traditional Chinese medical science blood stasis, fasting glucose 240mg/dI (± 60mg/dI) person; While is with the one of the complication such as hypertension, coronary heart disease, cerebrovascular, retinopathy, extremity vascular disease, lower limb vascular disease, nephropathy.Take Therapeutic Method: take that the embodiment of the present invention 3 produces to the medicative blood vessels peace of diabetes tool Jiangtang capsule, every day 3 times, each 2, every content of dispersion 0.5g, 1 month was 1 course for the treatment of, observed therapeutic effect.
Following medical science index is tested, judge therapeutic effect.
Hematodinamics: hemorheology; Platelet aggregation; Fibronectin and catabolite thereof (FDP); Venous oxygen content etc.
Analysis of blood lipid: measure T-CHOL; Triglyceride; Beta Lipoprotein; High density lipoprotein.
Immunologic assay: IL-Z; T cell function; Interleukin-22 produces ability.
Islet function is measured: serum insulin; C-peptide; Glucagon; Glucose tolerance; Insulin antibody.
Routine inspection project, treatment is front and finish each survey once; Within in treatment every 20 days, survey once.
Blood sugar detection: fasting glucose; 24h glucose in urine is quantitative; Routine urinalysis.
Renal function is measured: blood urea nitrogen (BUN); Blood thigh acid anhydride (Cr).
Liver functional testing: GPT; TTT; HBsAg.
Therapeutic effect criterion: effective judgement: all after treatment, symptom and the basic disappearance of blood stasis body card; 5 of hemorheologys, 2 of fibrinolytic systems, all improve; Fasting glucose≤110mg/dI; 24h glucose in urine≤5g or glucose in urine are treated front decline for effective.
Good effect is judged: after all treatments, symptom and blood stasis body prove aobvious alleviating; Hemorheology and fibrinolytic system totally 4 or 4 improve above; Fasting glucose≤150mg/dI;
24h glucose in urine≤10g or glucose in urine are treated front decline >=30% for good effect.
Invalid judgement: through treatment in 3 months, do not reach good effect person without cause specific.
Therapeutic effect statistics: effective number of cases 7, good effect number of cases 2, invalid number of cases 1.
Typical cases is given an example: Tang Sanping, and man, 61 years old, without obvious inducement, there is polydipsia, polyuria, become thin in patient before 2 years; Patient examination blood glucose 230mg, Western medicine diagnose is diabetes, tcm diagnosis: the cloudy Blood stasis that loses of the deficiency of vital energy, the rule for the treatment of: supplementing QI and nourishing YIN, activating blood circulation to dissipate blood stasis, through " to the medicative blood vessels peace of diabetes tool Jiangtang capsule " treatment, after January, symptom disappears substantially, and blood glucose is at 115g left and right, each transference cure.Remaining reinspection bimester of adhering to taking medicine: blood glucose maintains between 100～120mg, glucose in urine (-), hemorheological indexes is all in normal range.Doctor's advice: temperance for food and drink, having regular daily life, the consolidation of adhering to taking medicine.
The above; be only the specific embodiment of the present invention, but protection scope of the present invention is not limited to this, any be familiar with those skilled in the art the present invention disclose technical scope in; can expect easily changing or replacing, within all should being encompassed in protection scope of the present invention.Therefore, protection scope of the present invention should described be as the criterion with the protection domain of claim.
Claims (1)
1. to the medicative blood vessels peace of a diabetes tool Jiangtang capsule, it is characterized in that: the raw material by following weight portion is made:
10～40 parts of Radix Notoginseng, 10～60 parts of Sanguis Draxonis, by described Radix Notoginseng, Sanguis Draxonis carries out respectively disinfection by ultraviolet light, pulverizes respectively 50-90 mesh sieves, carries out mix and blend according to the components by weight of described technical scheme, is then distributed into capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410064096.8A CN103784684A (en) | 2014-02-25 | 2014-02-25 | Xuemaian blood glucose lowering capsule with therapeutic action on diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410064096.8A CN103784684A (en) | 2014-02-25 | 2014-02-25 | Xuemaian blood glucose lowering capsule with therapeutic action on diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103784684A true CN103784684A (en) | 2014-05-14 |
Family
ID=50661021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410064096.8A Pending CN103784684A (en) | 2014-02-25 | 2014-02-25 | Xuemaian blood glucose lowering capsule with therapeutic action on diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103784684A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113304230A (en) * | 2021-05-18 | 2021-08-27 | 江苏省人民医院（南京医科大学第一附属医院） | Traditional Chinese medicine composition for treating diabetic foot and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1170600A (en) * | 1997-05-08 | 1998-01-21 | 曾力群 | Pure Chinese drug tangniaojing for curing diabetes |
| CN101313968A (en) * | 2008-07-25 | 2008-12-03 | 西双版纳版纳药业有限责任公司 | Pseudo-ginseng dragon's blood preparation |
-
2014
- 2014-02-25 CN CN201410064096.8A patent/CN103784684A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1170600A (en) * | 1997-05-08 | 1998-01-21 | 曾力群 | Pure Chinese drug tangniaojing for curing diabetes |
| CN101313968A (en) * | 2008-07-25 | 2008-12-03 | 西双版纳版纳药业有限责任公司 | Pseudo-ginseng dragon's blood preparation |
Non-Patent Citations (5)
| Title |
|---|
| 侯少贞等: "三七水提物治疗2型糖尿病大鼠的实验研究", 《广东药学院学报》 * |
| 刘绍峻等: "辨证论治糖尿病用药规律探讨", 《中医药学报》 * |
| 刘舟等: "张发荣治疗糖尿病常用药对举隅", 《浙江中医药大学学报》 * |
| 张汝学等: "血竭对大鼠血糖、血浆胰岛素及血脂的影响", 《中药新药与临床药理》 * |
| 朱志远等: "中医药治疗2型糖尿病的研究进展", 《四川中医》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113304230A (en) * | 2021-05-18 | 2021-08-27 | 江苏省人民医院（南京医科大学第一附属医院） | Traditional Chinese medicine composition for treating diabetic foot and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103637179B (en) | Food composition with functions of lowering blood sugar and blood fat and improving fatty liver | |
| CN101690789B (en) | Chinese medicinal preparation for treating diabetes | |
| CN104758353B (en) | A kind of pharmaceutical composition and its preparation method and application for treating angiocardiopathy | |
| CN101843694A (en) | Chinese medicament for treating chronic hepatitis | |
| CN103463464B (en) | A kind of to the medicative healthy medicated wine of diabetes tool | |
| CN103989996B (en) | It is a kind of to treat Chinese medicine composition of diabetes and preparation method thereof | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN103479754A (en) | Hypotensive drug and preparation method thereof | |
| CN1315499C (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN109771578A (en) | The composition for preventing and treating diabetes and complication | |
| CN100509025C (en) | A medicine for treating diabetes | |
| CN102319376B (en) | Chinese herbal medicament for treating nephropathy | |
| CN105434802A (en) | Pharmaceutical composition for treating diabetes, and preparation method and application thereof | |
| CN105194301A (en) | Traditional Chinese medicine preparation for treating chronic cardiac failure | |
| CN102886019A (en) | Traditional Chinese medicinal blood sugar reducing plaster | |
| CN101361907B (en) | Hypoglycemic, antihypertensive formulation and preparation technique thereof | |
| CN104147544A (en) | Traditional Chinese medicinal composition for treating chronic anal cryptitis | |
| CN103784684A (en) | Xuemaian blood glucose lowering capsule with therapeutic action on diabetes | |
| CN103933282B (en) | A kind of Chinese medicinal capsule for treating diabetes | |
| CN103933386B (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof | |
| CN103495115B (en) | A kind of to the medicative medicated wine of diabetes tool | |
| CN106109951A (en) | Prevent and treat medicine of hyperglycemia, hyperlipidemia, hypertension and preparation method thereof | |
| CN104547105A (en) | Agent for reducing blood glucose | |
| CN105311470A (en) | Application of pharmaceutical composition containing folium artemisiae argyi in preparing medicine for treating diabetic nephropathy | |
| CN103784893A (en) | Medicine for treating sequela of cerebra apoplexy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140514 |